home / stock / stro / stro quote
Last: | $3.84 |
---|---|
Change Percent: | 1.99% |
Open: | $3.74 |
Close: | $3.765 |
High: | $3.86 |
Low: | $3.7101 |
Volume: | 119,132 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.84 | $3.74 | $3.765 | $3.86 | $3.7101 | 119,132 | 07-22-2024 |
$3.765 | $3.76 | $3.765 | $3.815 | $3.65 | 518,899 | 07-19-2024 |
$3.72 | $4.01 | $3.72 | $4.11 | $3.715 | 653,119 | 07-18-2024 |
$4.06 | $4 | $4.06 | $4.218 | $3.9703 | 790,054 | 07-17-2024 |
$4.07 | $4.22 | $4.07 | $4.36 | $4.06 | 1,221,468 | 07-16-2024 |
$4.22 | $4.17 | $4.22 | $4.39 | $4.1 | 1,057,341 | 07-15-2024 |
$4.16 | $3.95 | $4.16 | $4.43 | $3.85 | 1,151,526 | 07-12-2024 |
$3.96 | $3.67 | $3.96 | $3.97 | $3.62 | 1,001,349 | 07-11-2024 |
$3.6 | $3.38 | $3.6 | $3.61 | $3.31 | 1,071,236 | 07-10-2024 |
$3.36 | $3.03 | $3.36 | $3.425 | $3.015 | 1,137,987 | 07-09-2024 |
$3.04 | $2.92 | $3.04 | $3.1 | $2.92 | 650,902 | 07-08-2024 |
$2.92 | $2.86 | $2.92 | $2.94 | $2.75 | 667,973 | 07-05-2024 |
$2.88 | $2.95 | $2.88 | $3.07 | $2.87 | 414,870 | 07-04-2024 |
$2.88 | $2.95 | $2.88 | $3.07 | $2.87 | 414,870 | 07-03-2024 |
$2.96 | $3.04 | $2.96 | $3.04 | $2.82 | 621,475 | 07-02-2024 |
$3.05 | $2.9 | $3.05 | $3.065 | $2.89 | 1,015,749 | 07-01-2024 |
$2.93 | $2.94 | $2.93 | $3.04 | $2.79 | 3,878,990 | 06-28-2024 |
$2.92 | $2.92 | $2.92 | $2.99 | $2.88 | 580,872 | 06-27-2024 |
$2.935 | $2.99 | $2.935 | $3.04 | $2.76 | 1,612,839 | 06-26-2024 |
$2.99 | $3.08 | $2.99 | $3.095 | $2.955 | 1,040,487 | 06-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...